Literature DB >> 16990106

Immunophenotyping and differential diagnosis of hairy cell leukemia.

Estella Matutes1.   

Abstract

HCL and HCL-variant cells have a distinct immunophenotype that seems to correspond to that of a mature activated memory B cell. Although the two diseases have similarities in histology and membrane marker expression, such as the selected Ig heavy-chain expression and the reactivity with certain B-cell activation markers (eg, CD103), there are differences in their clinical course, morphology, and immunophenotype. Immunophenotyping is an essential tool for the diagnosis of these two disorders, for monitoring and assessing response to therapy, and for distinguishing them from other B-cell malignancies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16990106     DOI: 10.1016/j.hoc.2006.06.012

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  19 in total

1.  Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.

Authors:  Liqiang Xi; Evgeny Arons; Winnifred Navarro; Katherine R Calvo; Maryalice Stetler-Stevenson; Mark Raffeld; Robert J Kreitman
Journal:  Blood       Date:  2011-12-30       Impact factor: 22.113

2.  Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.

Authors:  Mauricio Burotto; Maryalice Stetler-Stevenson; Evgeny Arons; Hong Zhou; Wyndham Wilson; Robert J Kreitman
Journal:  Clin Cancer Res       Date:  2013-10-04       Impact factor: 12.531

3.  Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome.

Authors:  Evgeny Arons; Sharon Adams; David J Venzon; Ira Pastan; Robert J Kreitman
Journal:  Br J Haematol       Date:  2014-06-13       Impact factor: 6.998

Review 4.  Update on the biology and treatment options for hairy cell leukemia.

Authors:  Preetesh Jain; Naveen Pemmaraju; Farhad Ravandi
Journal:  Curr Treat Options Oncol       Date:  2014-06

Review 5.  Immunoconjugates in the management of hairy cell leukemia.

Authors:  Robert J Kreitman; Ira Pastan
Journal:  Best Pract Res Clin Haematol       Date:  2015-10-09       Impact factor: 3.020

6.  Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria.

Authors:  Haipeng Shao; Katherine R Calvo; Marlene Grönborg; Prashant R Tembhare; Robert J Kreitman; Maryalice Stetler-Stevenson; Constance M Yuan
Journal:  Leuk Res       Date:  2013-01-22       Impact factor: 3.156

Review 7.  How I treat hairy cell leukemia.

Authors:  Michael R Grever
Journal:  Blood       Date:  2009-10-20       Impact factor: 22.113

Review 8.  Approach to the patient after relapse of hairy cell leukemia.

Authors:  Robert J Kreitman; David J P Fitzgerald; Ira Pastan
Journal:  Leuk Lymphoma       Date:  2009-10

9.  Impact of telomere length on survival in classic and variant hairy cell leukemia.

Authors:  Evgeny Arons; Hong Zhou; Daniel C Edelman; Allison Gomez; Seth M Steinberg; David Petersen; Yonghong Wang; Paul S Meltzer; Robert J Kreitman
Journal:  Leuk Res       Date:  2015-09-24       Impact factor: 3.156

10.  VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.

Authors:  Evgeny Arons; Tara Suntum; Maryalice Stetler-Stevenson; Robert J Kreitman
Journal:  Blood       Date:  2009-09-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.